Search the Newsreel

Walleye Capital LLC Invests $2.44 Million in REGENXBIO Inc. $RGNX

Walleye Capital LLC has invested $2.44 million in REGENXBIO Inc. by acquiring 203,726 shares during the second quarter, making them one of many institutional investors in the company. REGENXBIO exceeded analyst expectations with its recent earnings report, posting $0.43 EPS and $108.02 million in …

T. Rowe Price (ARGX) discloses 2.68M argenx SE ADRs with 4.3% ownership

T. Rowe Price Associates, Inc. has disclosed a beneficial ownership of 2,675,457 argenx SE ADRs as of June 30, 2026, representing a 4.3% stake. The firm holds sole voting power over 2,649,465 ADRs and sole dispositive power over all 2,675,457 ADRs, explicitly denying beneficial …

argenx SE: Objectif de Cours et Consensus des Analystes | ARGX | NL0010832176

Argenx stock steadies after Forte Biosciences deal and post-earnings pullback

Argenx stock is consolidating after a strong Q2 2026 earnings beat and a significant $2.2 billion acquisition of Forte Biosciences. Despite a recent pullback, the stock remains in positive territory year-to-date, with analysts maintaining a constructive outlook and an implied upside of roughly 23% …

REGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at Zacks Research

Zacks Research has upgraded REGENXBIO (NASDAQ:RGNX) from a "strong sell" to a "hold" rating. This upgrade comes as the biotechnology company exceeded revenue and EPS estimates in its latest quarterly report, though it remains unprofitable. Institutional investors hold a significant portion of the company's …

Assenagon Asset Management S.A. Has $2.03 Million Position in REGENXBIO Inc. $RGNX

Assenagon Asset Management S.A. significantly reduced its stake in REGENXBIO Inc. by 82.7% in the second quarter, now holding 169,279 shares valued at $2.03 million. Despite this, institutional investors still own a substantial 88.08% of the company. REGENXBIO recently surpassed analyst estimates for quarterly …

GreenX Metals Leads 3 ASX Penny Stocks To Monitor

(RGNX) as a Liquidity Pulse for Institutional Tactics

This article provides an AI-driven analysis of Regenxbio Inc. (NASDAQ: RGNX), highlighting mixed sentiment and a mid-channel oscillation pattern. It outlines institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry, target, and stop-loss levels. The analysis also includes a …

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX) for alleged federal securities law violations. The lawsuit claims that REGENXBIO made materially false and misleading statements regarding the development and commercialization of RGX‑111 for severe MPS I. …

Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences

argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, …

argenx (ENXTBR:ARGX) Draws Fresh Valuation Debate, Is The Stock Overvalued Or Undervalued?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recent share performance and business profile Without a single clear news event driving headlines, …

argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how …

Mining Stocks: What Could Put GreenX Metals Back in Market Focus?

H.C. Wainwright lowers Regenxbio stock price target on equity offering

H.C. Wainwright has lowered its price target for Regenxbio (NASDAQ:RGNX) to $23 from $26, while maintaining a Buy rating, following the company's public offering of common stock in July 2026. This adjustment comes as Regenxbio reported Q2 2026 revenue of $108 million, including a …

argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical …

RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of REGENXBIO Inc. to Contact the Firm Today!

Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against REGENXBIO Inc. (NASDAQ:RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO made materially false and misleading statements regarding the development …

Regenxbio Inc (RGNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

REGENXBIO (RGNX) Stock Drops Despite Profit Surprise And Longer Cash Runway

REGENXBIO (RGNX) experienced a nearly 5% stock drop despite reporting a surprise profit of US$0.43 EPS and US$108 million in revenue for Q2 2026, swinging from a significant loss. The company also extended its cash runway into Q4 2027 due to funding from AbbVie …

Bank of America Securities Reaffirms Their Buy Rating on RegenXBio (RGNX)

argenx SE (ARGX) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on argenx SE (ARGX), a commercial-stage biopharmaceutical company focused on autoimmune diseases. It details the company's stock performance, key financial metrics, product pipeline, strategic partnerships, and analyst ratings. The article highlights argenx's main product, VYVGART, and several …

argenx SE (ARGX) Aktuelle Aktien-News

REGENXBIO Inc. Stock 12‑Month Price Target Raised to $26.17, Implies 149% Upside

Analysts have raised REGENXBIO Inc.'s average 12-month price target from $26 to $26.17, indicating a potential upside of approximately 149% from its August 5 closing price. The consensus rating for RGNX remains a "Buy" among 12 analysts, with 11 recommending a Buy and 1 …

Barclays downgrades Regenxbio stock rating on regulatory uncertainty

Barclays downgraded Regenxbio Inc. (NASDAQ:RGNX) to Equalweight from Overweight, setting a price target of $12.00 due to regulatory uncertainty surrounding its Duchenne muscular dystrophy (DMD) program and competitive landscape for wet age-related macular degeneration (wet AMD). Despite a recent 16% stock increase, the firm …

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics HALO reported second-quarter 2026 adjusted earnings of $2.28 per share, which comprehensively beat the Zacks Consensus Estimate of $1.82. Earnings rose 48.1% year over year. Total revenues in the second quarter increased 48% year over year to $481 million. Revenues also surpassed …

GreenX Metals Applies to Quote 283,954 Shares Issued for Eleonore North Exploration Licence

GreenX Metals Seeks ASX Quotation for Additional Ordinary Shares

GreenX Metals Announces Issuance of 283,954 Ordinary Shares via Section 708A Notice

Euronext announces volumes for July 2026

Euronext Paris SA Euronext announces volumes for July 2026 Amsterdam, Athens, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 6 August 2026– Euronext, the leading European capital market infrastructure, today announced trading volumes for July 2026. Monthly and historical volume tables are available at …

REGENXBIO (Nasdaq: RGNX) turns Q2 profit on $100M AbbVie milestone

REGENXBIO (Nasdaq: RGNX) reported a significant turnaround in Q2 2026, posting a net income of $22.7 million ($0.43 per share) compared to a $70.9 million net loss in Q2 2025. This profit was largely driven by $108.0 million in total revenues, primarily from a …

Earnings call transcript: REGENXBIO beats on Q2 2026 EPS, shares rise premarket

REGENXBIO reported Q2 2026 adjusted EPS of $0.43, significantly beating the $0.25 forecast, though revenue of $108.02 million missed estimates. Shares rose premarket due to a strengthened balance sheet, with pro forma cash exceeding $310 million after a $100 million AbbVie milestone and a …

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx SE August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a tender offer to …

argenx SE: argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx SE announced the commencement of a tender offer to acquire all outstanding shares of Forte Biosciences, Inc. for $77.00 per share in cash. This acquisition will make Forte Biosciences a wholly-owned subsidiary of argenx. Forte's Board of Directors has recommended that shareholders accept …

REGENXBIO Inc. Quarterly Earnings Report